Exelixis and Iconic Therapeutics enter into exclusive option and license agreement
Exelixis announced it has entered into an exclusive option and license agreement with Iconic Therapeutics to advance an innovative next-generation antibody-drug conjugate program for cancer. This agreement with Iconic is Exelixis’ second strategic collaboration focused on novel biologics. May 16, 2019